Ruxolitinib is used to treat some types of myeloproliferative neoplasms (MPNs) – blood cancers in which there is an excessive production of blood cells e.g. myelofibrosis or polycythaemia vera
Inform your doctor if any of the following occurs:
If you are pregnant or planning to become pregnant, inform your doctor. If you think you may be pregnant while on Ruxolitinib, inform your doctor immediately so that he or she may discuss alternative treatments with you.
Do not breastfeed while on ruxolitinib and for 2 weeks after the final dose.
The dose you start on depends on your blood test results and the condition you have. Your doctor may need to change this dose throughout the treatment by checking your blood tests regularly.
If you miss a dose of Ruxolitinib, take your next dose at your regular time. Do not take 2 doses at the same time.